文献速递肿瘤 PET/CT骨显像与常规 SPECT

慢性肾病患者大型肾脏肿块的99mTc-MIBI SPECT/CT评估

Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease.
PubMed 文献 · Clin Nucl Med · 2017-01-01

本文报告一例84岁慢性肾病患者,发现11.2 cm肾脏肿块,CT或MRI难以可靠区分良性/惰性肾肿块与侵袭性肿瘤,肾肿块活检有并发症风险且10%至20%结果无法诊断。99mTc-MIBI SPECT/CT结果使患者避免了根治性肾切除术。

要点

  • CT或MRI无法可靠区分良性/惰性肾肿块与侵袭性肿瘤。
  • 肾肿块活检有并发症风险,10%至20%结果无法诊断。
  • 99mTc-MIBI SPECT/CT可准确区分良性肾嗜酸细胞瘤及混合嗜酸细胞/嫌色细胞肿瘤与其他侵袭性肾肿瘤类型。

核心结论

  • 99mTc-MIBI SPECT/CT结果使该84岁慢性肾病伴11.2 cm肾脏肿块患者避免了根治性肾切除术。

研究设计与样本

  • 本文为病例报告,报告一例84岁慢性肾病伴11.2 cm肾脏肿块男性患者。

主要发现

  • 患者为84岁男性,患有慢性肾病,肾脏肿块大小为11.2 cm。
  • 99mTc-MIBI SPECT/CT结果使患者避免了根治性肾切除术。

关键数值与推荐

  • CT或MRI无法可靠区分良性/惰性肾肿块与侵袭性肿瘤组织学类型。
  • 肾肿块活检有并发症风险,无法诊断率为10%至20%。
  • 99mTc-MIBI SPECT/CT已被证明可准确区分良性肾嗜酸细胞瘤及混合嗜酸细胞/嫌色细胞肿瘤与其他更具侵袭性的肾肿瘤类型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The differentiation of benign and indolent renal masses from aggressive tumor histologies cannot be reliably performed by CT or MRI. Additionally, renal mass biopsy risks complications and has a nondiagnostic rate of 10% to 20%. Tc-MIBI SPECT/CT has been shown to allow for the accurate differentiation of benign renal oncocytomas and hybrid oncocytic/chormophobe tumors from other more aggressive renal tumor types. We present the case of an 84-year-old man with chronic kidney disease and an 11.2-cm renal mass. Results of his Tc-MIBI SPECT/CT allowed avoidance of a radical nephrectomy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rowe SP, Gorin MA, Javadi MS, et al. Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease. Clin Nucl Med. 2017. PMID: 28072625. doi:10.1097/RLU.0000000000001533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。